A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 23, 2020

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions
Gastrointestinal Cancer
Interventions
BIOLOGICAL

TMV-018 + 5-FC

"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment."

BIOLOGICAL

TMV-018 + anti-PD-1

"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~Anti-PD-1 inhibitor dose according to its SMPC."

BIOLOGICAL

TMV-018 + 5-FC + anti-PD-1

"TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment cycle.~Anti-PD-1 Inhibitor: dose according to its SMPC."

Trial Locations (2)

Unknown

University Hospital Bonn, Bonn

University Hospital Tübingen, Tübingen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Assign Data Management and Biostatistics GmbH

OTHER

collaborator

Optimapharm

INDUSTRY

lead

Themis Bioscience GmbH

INDUSTRY